Company registration number SC264409 (Scotland)
LUSTRE SKIN LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025
PAGES FOR FILING WITH REGISTRAR
LUSTRE SKIN LTD
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 10
LUSTRE SKIN LTD
BALANCE SHEET
AS AT
30 JUNE 2025
30 June 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
-
0
464
Tangible assets
4
19,422
7,025
19,422
7,489
Current assets
Stocks
142,874
233,554
Debtors
5
278,726
113,391
Cash at bank and in hand
12,430
271,260
434,030
618,205
Creditors: amounts falling due within one year
6
(427,448)
(260,969)
Net current assets
6,582
357,236
Total assets less current liabilities
26,004
364,725
Creditors: amounts falling due after more than one year
7
(2,250)
(7,125)
Net assets
23,754
357,600
Capital and reserves
Called up share capital
9
121,064
51,156
Share premium account
15,350,097
14,597,311
Other reserves
8
2,686
-
0
Profit and loss reserves
(15,450,093)
(14,290,867)
Total equity
23,754
357,600
LUSTRE SKIN LTD
BALANCE SHEET (CONTINUED)
AS AT
30 JUNE 2025
30 June 2025
- 2 -

For the financial year ended 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 29 July 2026 and are signed on its behalf by:
D Grech
D Grech
Director
Company registration number SC264409 (Scotland)
LUSTRE SKIN LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025
- 3 -
1
Accounting policies
Company information

Lustre Skin Ltd is a private company limited by shares incorporated in Scotland. The registered office is Alba Innovation Centre, Rosebank, Livingston, West Lothian, Scotland, EH54 7GA.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

The directors have assessed the company's ability to continue as a going concern and are satisfied that it remains appropriate to prepare the financial statements on that basis. In making this assessment, the directors have considered the continued support of the company's shareholders, including funding provided following the year end, together with the company's expected cash flow requirements. The directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future and, accordingly, have adopted the going concern basis in preparing these financial statements.true

1.3
Revenue

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

 

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.4
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.5
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

LUSTRE SKIN LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 4 -

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Website costs
5 years straight line
1.6
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
3 years straight line
Computers
3 years straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.7
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

LUSTRE SKIN LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 5 -
1.8
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.9
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.10
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

LUSTRE SKIN LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 6 -
Other financial liabilities

Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.

 

Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

1.11
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13
Retirement benefits

The company operates a defined contribution plan for it's employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations. The contributions are recognised as an expense in the Statement of comprehensive income when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the company in independently administered funds.

1.14
Share-based payments

Equity-settled share-based payments are measured at fair value at the date of grant by reference to the fair value of the equity instruments granted using the Black Scholes model. The fair value determined at the grant date is expensed on a straight-line basis over the vesting period, based on the estimate of shares that will eventually vest. A corresponding adjustment is made to equity.

LUSTRE SKIN LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 7 -

When the terms and conditions of equity-settled share-based payments at the time they were granted are subsequently modified, the fair value of the share-based payment under the original terms and conditions and under the modified terms and conditions are both determined at the date of the modification. Any excess of the modified fair value over the original fair value is recognised over the remaining vesting period in addition to the grant date fair value of the original share-based payment. The share-based payment expense is not adjusted if the modified fair value is less than the original fair value.

 

Cancellations or settlements (including those resulting from employee redundancies) are treated as an acceleration of vesting and the amount that would have been recognised over the remaining vesting period is recognised immediately.

1.15
Leases
As lessee

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
5
10
3
Intangible fixed assets
Website costs
£
Cost
At 1 July 2024
9,290
Disposals
(9,290)
At 30 June 2025
-
0
Amortisation and impairment
At 1 July 2024
8,826
Amortisation charged for the year
464
Disposals
(9,290)
At 30 June 2025
-
0
Carrying amount
At 30 June 2025
-
0
At 30 June 2024
464
LUSTRE SKIN LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
- 8 -
4
Tangible fixed assets
Plant and equipment
Computers
Total
£
£
£
Cost
At 1 July 2024
117,560
27,396
144,956
Additions
19,339
-
0
19,339
Disposals
-
0
(16,581)
(16,581)
At 30 June 2025
136,899
10,815
147,714
Depreciation and impairment
At 1 July 2024
111,718
26,213
137,931
Depreciation charged in the year
5,842
1,100
6,942
Eliminated in respect of disposals
-
0
(16,581)
(16,581)
At 30 June 2025
117,560
10,732
128,292
Carrying amount
At 30 June 2025
19,339
83
19,422
At 30 June 2024
5,842
1,183
7,025
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
240,486
47,718
Other debtors
38,240
65,673
278,726
113,391
6
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans
4,500
4,500
Trade creditors
234,111
126,004
Taxation and social security
60,499
27,913
Other creditors
128,338
102,552
427,448
260,969

The company has entered into a foreign exchange forward contract to purchase USD 100,000 at a fixed sterling amount. The contract is measured at fair value at the balance sheet date and a derivative liability of £5,052 has been recognised within other creditors due within one year. The resulting fair value loss of £5,052 has been recognised in profit or loss.

LUSTRE SKIN LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
- 9 -
7
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
2,250
7,125
8
Share-based payment transactions

Details of the employee share option plan of the Company

The Company had a share option scheme for employees during the year ended 30 June 2025. The options vested immediately on the date of grant and are exercisable at the year end. The charge has been recognised immediately as an expense in profit or loss, with a corresponding credit recognised within equity.

 

The following share based payment arrangements were in existence during the year ended 30 June 2025.

Number of share options
Weighted average exercise price
2025
2024
2025
2024
Number
Number
£
£
Outstanding at 1 July 2024
-
0
-
0
-
0
-
0
Granted
89,536
-
0
0.06
-
0
Outstanding at 30 June 2025
89,536
-
0
0.06
-
0
Exercisable at 30 June 2025
89,536
-
0
0.06
-
0

The options outstanding at 30 June 2025 had an exercise price of £0.06, and a remaining contractual life of 3 years.

The fair value of the Employment Options is estimated at the date of the grant using a Black-Scholes option pricing model. The following assumptions have been used in calculating the fair value of the share options.

 

Inputs were as follows:

2025
Share price at grant date
£0.066
Exercise price
£0.06
Expected volatility
70%
Expected life
3 years
Risk free rate
3.95%
Expected dividends yields
0%
The risk free interest rate is based on the government gilt rate that is commensurate with the average expected life of the option. The expected life of the option is the expected average point at which the option becomes exercisable. The volatility is based on historical volatility of the share price of the Company and of quoted comparable companies over the most recent period at the date of the grant that is commensurate with the average expected life of the option. The weighted average share price used in each calculation was equal to the option exercise price.
LUSTRE SKIN LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
8
Share-based payment transactions
(Continued)
- 10 -
2025
2024
£
£
Expenses recognised in the year
Arising from equity-settled transactions
2,686
-
9
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
B Ordinary Shares of 0.2p each
56,635,836
21,681,755
113,272
43,364
C Ordinary Shares of 0.2p each
3,896,059
3,896,059
7,792
7,792
60,531,895
25,577,814
121,064
51,156
2025-06-302024-07-01falsefalsefalse29 July 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityC D OutramR J PetersenA TealG A TownK J S GrahamMr S J LeadbeaterD GrechSC2644092024-07-012025-06-30SC2644092025-06-30SC2644092024-06-30SC264409core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-06-30SC264409core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-06-30SC264409core:PlantMachinery2025-06-30SC264409core:ComputerEquipment2025-06-30SC264409core:PlantMachinery2024-06-30SC264409core:ComputerEquipment2024-06-30SC264409core:CurrentFinancialInstrumentscore:WithinOneYear2025-06-30SC264409core:CurrentFinancialInstrumentscore:WithinOneYear2024-06-30SC264409core:Non-currentFinancialInstrumentscore:AfterOneYear2025-06-30SC264409core:Non-currentFinancialInstrumentscore:AfterOneYear2024-06-30SC264409core:CurrentFinancialInstruments2025-06-30SC264409core:CurrentFinancialInstruments2024-06-30SC264409core:ShareCapital2025-06-30SC264409core:ShareCapital2024-06-30SC264409core:SharePremium2025-06-30SC264409core:SharePremium2024-06-30SC264409core:OtherMiscellaneousReserve2025-06-30SC264409core:OtherMiscellaneousReserve2024-06-30SC264409core:RetainedEarningsAccumulatedLosses2025-06-30SC264409core:RetainedEarningsAccumulatedLosses2024-06-30SC264409core:ShareCapitalOrdinaryShareClass12025-06-30SC264409core:ShareCapitalOrdinaryShareClass12024-06-30SC264409core:ShareCapitalOrdinaryShareClass22025-06-30SC264409core:ShareCapitalOrdinaryShareClass22024-06-30SC264409core:ShareCapitalOrdinaryShares2025-06-30SC264409core:ShareCapitalOrdinaryShares2024-06-30SC264409bus:Director72024-07-012025-06-30SC264409core:IntangibleAssetsOtherThanGoodwill2024-07-012025-06-30SC264409core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-07-012025-06-30SC264409core:PlantMachinery2024-07-012025-06-30SC264409core:ComputerEquipment2024-07-012025-06-30SC2644092023-07-012024-06-30SC264409core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-06-30SC264409core:PlantMachinery2024-06-30SC264409core:ComputerEquipment2024-06-30SC2644092024-06-30SC264409core:Non-currentFinancialInstruments2025-06-30SC264409core:Non-currentFinancialInstruments2024-06-30SC2644092023-06-30SC264409bus:OrdinaryShareClass12024-07-012025-06-30SC264409bus:OrdinaryShareClass22024-07-012025-06-30SC264409bus:OrdinaryShareClass12025-06-30SC264409bus:OrdinaryShareClass12024-06-30SC264409bus:OrdinaryShareClass22025-06-30SC264409bus:OrdinaryShareClass22024-06-30SC264409bus:AllOrdinaryShares2025-06-30SC264409bus:AllOrdinaryShares2024-06-30SC264409bus:PrivateLimitedCompanyLtd2024-07-012025-06-30SC264409bus:SmallCompaniesRegimeForAccounts2024-07-012025-06-30SC264409bus:FRS1022024-07-012025-06-30SC264409bus:AuditExemptWithAccountantsReport2024-07-012025-06-30SC264409bus:Director12024-07-012025-06-30SC264409bus:Director22024-07-012025-06-30SC264409bus:Director32024-07-012025-06-30SC264409bus:Director42024-07-012025-06-30SC264409bus:Director52024-07-012025-06-30SC264409bus:Director62024-07-012025-06-30SC264409bus:FullAccounts2024-07-012025-06-30xbrli:purexbrli:sharesiso4217:GBP